- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | Rodman & Renshaw initiates SAB Biotherapeutics stock with buy rating | 1 | Investing.com | ||
| 31.03. | SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 19.03. | SAB Biotherapeutics, Inc.: SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants | 3 | GlobeNewswire (USA) | ||
| 18.03. | SAB BioTherapeutics slips 5%, prices $85M stock offering | 1 | Seeking Alpha | ||
| 18.03. | SAB Biotherapeutics prices $85M stock offering at $3.85/share | 4 | Investing.com | ||
| 18.03. | SAB Biotherapeutics, Inc.: SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.03. | SAB Biotherapeutics, Inc.: SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 11.03. | H.C. Wainwright cuts SAB Biotherapeutics price target to $7 on dilution | 1 | Investing.com | ||
| 10.03. | SAB Biotherapeutics reports early C-peptide signals in phase 1 trial | 3 | Investing.com | ||
| 10.03. | SAB Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | SAB Biotherapeutics, Inc.: SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes | 336 | GlobeNewswire (Europe) | Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE... ► Artikel lesen | |
| 09.03. | SAB BioTherapeutics reports FY results | 3 | Seeking Alpha | ||
| 09.03. | SAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2025 Financial Results and Business Highlights | 229 | GlobeNewswire (Europe) | Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H... ► Artikel lesen | |
| 09.03. | SAB Biotherapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 07.01. | SAB Biotherapeutics, Inc.: SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director | 2 | GlobeNewswire (USA) | ||
| 07.01. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential | 5 | Investing.com | ||
| 18.12.25 | SAB Biotherapeutics, Inc.: First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D | 297 | GlobeNewswire (Europe) | Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:... ► Artikel lesen | |
| 17.12.25 | SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D | 237 | GlobeNewswire (Europe) | Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteersStudy results support the chronic dosing... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| VIKING THERAPEUTICS | 28,950 | -0,86 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,443 | -6,24 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| INTELLIA THERAPEUTICS | 11,400 | -1,04 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| TEMPUS AI | 36,640 | +0,07 % | Trader-Interview mit Sascha Huber: Marvell Technology, Intuit, Salesforce, Tempus AI & MicroStrategy | In dieser Ausgabe des Trader-Interviews analysieren Andreas Bernstein und Sascha Huber die aktuelle Börsenlage und beleuchten ausgewählte Einzelwerte mit Fokus auf den Einfluss von Künstlicher Intelligenz... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,160 | +0,02 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,550 | +0,11 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,100 | +0,11 % | Johnson Fistel, PLLP: Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty | San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics... ► Artikel lesen | |
| EXELIXIS | 37,605 | -0,41 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,165 | +1,53 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,192 | +0,85 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| VAXART | 0,380 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 26.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.03.2026.ISIN NameCA2568277834 DOLLY... ► Artikel lesen |
Das Unternehmen SAB BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,075 (-1,96 %) liegt der Kurs bei 3,755 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAB BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.